Related Articles
Benefit from a high dose of gefitinib in a woman with lung adenocarcinoma and an epidermal growth factor receptor tyrosine-kinase acquired mutation
An update of the mechanisms of resistance to EGFR-tyrosine kinase inhibitors in breast cancer: Gefitinib (Iressa™)-induced changes in the expression and nucleo-cytoplasmic trafficking of HER-ligands (Review)
Deficient HER3 expression in poorly-differentiated colorectal cancer cells enhances gefitinib sensitivity
HER2 overexpression reverses the relative resistance of EGFR-mutant H1975 cell line to gefitinib
Small cell lung cancer cells express EGFR and tyrosine phosphorylation of EGFR is inhibited by gefitinib (‘Iressa’, ZD1839)